about
Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias.Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases.High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia.Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults.Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure.More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura.Comparative analysis of iron status and other hematological parameters in preeclampsia.Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in northeast Mexico.Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host diseaseAge Acts as an Adverse Independent Variable for Survival in Acute Lymphoblastic Leukemia: Data From a Cohort in Northeast Mexico.The treatment of CML at an environment with limited resources.Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial.Real-world outcomes of treatment for acute lymphoblastic leukemia during adolescence in a financially restricted environment: Results at a single center in Latin America.Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?Impact of outpatient non-myeloablative haematopoietic stem cell transplantation in quality of life vs. conventional therapy.Myelodysplasia and acute myeloid leukemia fifteen years after high-dose cyclophosphamide in a child with severe aplastic anemiaOutpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.Obesity is associated with higher overall survival in patients undergoing an outpatient reduced-intensity conditioning hematopoietic stem cell transplant.Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia.Platelet aggregation in children with acute lymphoblastic leukemia during induction of remission therapy.Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.No clinically relevant differences between capillary and venous blood cell counts in adult haematological patients using a nonautomated lancet.Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.Effective collection of peripheral blood stem cells in children weighing 20 kilogram or less in a single large-volume apheresis procedure.Characteristics and clinical evolution of patients with acute myeloblastic leukemia in northeast Mexico: an eight-year experience at a university hospital.Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease.Chemotherapy alone or HSCT after reduced-intensity conditioning for patients with malignant hematologic diseases are not associated to metabolic syndrome: a cross-sectional observational study.Mobilization kinetics of CD133+ hematoprogenitor cells for hematopoietic grafting.Feasibility of an outpatient HLA haploidentical stem cell transplantation program in children using a reduced-intensity conditioning regimen and CD3-CD19 depletion.Efficacy of mitoxantrone as frontline anthracycline during induction therapy in adults with newly diagnosed acute lymphoblastic leukemia: a single-center experience.Danazol as first-line therapy for aplastic anemia.Measurements of Catheter, Venous, and Capillary Cyclosporine A Blood Are Comparable and Useful in Pediatric Hematopoietic Stem Cell Transplant Recipients.Contributions of a regional approach to document hematologic disease in Mexico: a 10-year experience in an open populationLong-Term Insulin Independence in Type 1 Diabetes Mellitus Using a Simplified Autologous Stem Cell TransplantCultural factors related to adherence to imatinib in CML: A Mexican perspectiveSafety and Cost-Effectiveness of a Simplified Method for Lumbar Puncture in Patients with Hematologic MalignanciesAllogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different?More about Imatinib and Nilotinib Combination Therapy in Chronic Myeloid Leukemia
P50
Q33378052-2BEBBE16-0529-4C5F-A026-E646F7B60A8CQ33391868-72E0EE71-A643-4372-85E9-6FA10413AB40Q33406040-978AB0BC-F390-417C-9752-DFC7F5A819B4Q33406310-CE33F4F4-B5AA-4844-A8EC-F01C7212423BQ33415131-64422334-49B6-4B2C-8D5D-D86F81737396Q33429973-5CE97839-EFBF-4FE6-A7E4-FE41FF798DD6Q33430243-5E2957E7-D6EB-4E0A-8B52-6CC2FEF4F491Q33434838-B2EEDE3E-9DE8-43FB-B3D7-4F5AD9BC88CAQ35345538-39BC7014-C8F6-4149-869A-EDBFCC895307Q35930604-96C212BA-0E11-41C2-ABB5-1A9849666065Q38688174-C4208F4F-87CC-48C5-8FED-151B5927B0ACQ38842954-E3FE5459-922E-42C3-8945-66A9A6D72405Q40213971-D28D8EF4-C9D2-4A6F-BE0F-618B9A4E6076Q40427765-E84E8A32-AB32-43FA-9222-ADE0A39609B4Q41187347-C2857B22-754D-47F2-8C99-6880EE1CF69CQ41627517-CB671044-4217-4B76-AD54-DC676E06F8EDQ42318026-4A68F439-F530-400C-89E4-975081217CDCQ43057574-0A4A3C83-E0F4-480C-B4B0-0A9A75D24483Q43500413-6F12A818-993F-42D7-86E5-9BCAF538CA8AQ44703351-D4E4CC38-A4BA-486B-BDE7-120437B79513Q44792659-854578AA-CE9D-4F56-A082-228CF72F3832Q46494482-1DA4DC2A-0D85-470B-A3D0-0EEA04D484E6Q46956799-D1CFB556-EA64-4298-9B1C-D7006DC0CA97Q48213373-375C9F33-56D9-40A2-856A-FA0C40217CFAQ48466902-D96D4405-F2A5-4C0B-80A4-A4DA0FFCF531Q50454066-7411D356-1001-4AF6-92AE-48945F3A171FQ50719767-AF3CC49E-A4F0-4E65-BC70-3AE6AA2CD163Q50986967-0CC0E38E-7887-4310-B717-E05AB2666F01Q51320628-CDFAD32C-B40F-454F-8B53-A1D42B627213Q51799098-7C6F321D-6D0B-4F01-A6E1-9B7A555DD2D9Q51817075-8293212E-324F-4D3A-BAC0-4FE6D8A01A71Q52971812-D4019B10-A691-4881-B0CA-B7D121EC42C0Q53271319-20C568F1-5329-467B-B673-268584770A7FQ54369626-A47721E5-2219-4EC3-BFFA-53DD2E53FB63Q63240981-AA622E4D-1E81-4184-B11A-44A143D69B17Q63241025-59815395-DCCA-4A2F-9A47-4643E01E3F78Q63241039-BE7B4CCB-DD61-4B43-8DB2-FC489C804B48Q63241058-0A1139DB-2CBC-4080-AE05-26692F4B48E2Q63241063-6DE13583-A867-40C7-8EE5-7A50B55CE6C3Q63241089-98DFAA6D-CA74-4A81-A514-3CF7DF2C79FD
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Olga Graciela Cantú-Rodríguez
@ast
Olga Graciela Cantú-Rodríguez
@en
Olga Graciela Cantú-Rodríguez
@es
Olga Graciela Cantú-Rodríguez
@nl
Olga Graciela Cantú-Rodríguez
@sl
type
label
Olga Graciela Cantú-Rodríguez
@ast
Olga Graciela Cantú-Rodríguez
@en
Olga Graciela Cantú-Rodríguez
@es
Olga Graciela Cantú-Rodríguez
@nl
Olga Graciela Cantú-Rodríguez
@sl
prefLabel
Olga Graciela Cantú-Rodríguez
@ast
Olga Graciela Cantú-Rodríguez
@en
Olga Graciela Cantú-Rodríguez
@es
Olga Graciela Cantú-Rodríguez
@nl
Olga Graciela Cantú-Rodríguez
@sl
P106
P1153
6506657229
P21
P31
P496
0000-0003-2134-3734